DrugPatentWatch Database Preview
Puma Biotech Company Profile
What is the competitive landscape for PUMA BIOTECH, and what generic alternatives to PUMA BIOTECH drugs are available?
PUMA BIOTECH has one approved drug.
There are eight US patents protecting PUMA BIOTECH drugs.
There are ninety-three patent family members on PUMA BIOTECH drugs in twenty countries.
Summary for Puma Biotech
| International Patents: | 93 |
| US Patents: | 8 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Puma Biotech
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 9,139,558 | ➤ Sign Up | ➤ Sign Up | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,982,043 | ➤ Sign Up | ➤ Sign Up | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 9,211,291 | ➤ Sign Up | ➤ Sign Up | ||||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 8,518,446 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Puma Biotech | NERLYNX | neratinib maleate | TABLET;ORAL | 208051-001 | Jul 17, 2017 | RX | Yes | Yes | 7,399,865 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Puma Biotech
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,022,216 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | ➤ Sign Up |
| 8,394,959 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl)-4-(dimethylamino)-2-buteramide and crystalline forms thereof | ➤ Sign Up |
| 8,173,814 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quin- olinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Puma Biotech Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Taiwan | 201427954 | ➤ Sign Up |
| South Africa | 201108118 | ➤ Sign Up |
| European Patent Office | 2537843 | ➤ Sign Up |
| Mexico | 342681 | ➤ Sign Up |
| Mexico | 2010004173 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.
